Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 Operating Margin % is 17.72% as of Mar. 2026, which is 15% below its 10-year median of 20.82. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Accretion Nutraveda ranks better than 80.65% on this metric.
The historical rank and industry rank for Accretion Nutraveda's Operating Margin % or its related term are showing as below:
BOM:544694'
s Operating Margin % Range Over the Past 10 Years
Min: 16.42 Med: 20.82 Max: 23
Current: 19.43
BOM:544694's Operating Margin % is ranked better than 80.65% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.59
vs BOM:544694: 19.43
Accretion Nutraveda's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Accretion Nutraveda Operating Margin % Related Terms
Accretion Nutraveda Operating Margin % Historical Data
* Premium members only.
The historical data trend for Accretion Nutraveda's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda Operating Margin % Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Operating Margin %
16.42
23.00
21.89
19.74
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
Operating Margin %
0.00
0.00
22.71
21.82
17.72
BOM:544694 vs ZTS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Accretion Nutraveda's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a Operating Margin % of 17.72% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Accretion Nutraveda and its competitors. This is 15% below median its historical median of 20.82. Over the past decade, Accretion Nutraveda's Operating Margin % has ranged from 16.42 to 23.00. According to the industry distribution chart, Accretion Nutraveda ranks #186 out of 961 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Accretion Nutraveda's Operating Margin % too high?
Accretion Nutraveda's current Operating Margin % of 17.72% is 15% below median its 10-year median of 20.82. Over the past 10 years, this metric has ranged from a low of 16.42 to a high of 23.00. The Drug Manufacturers industry median Operating Margin % is 7.59. Accretion Nutraveda's value of 17.72% is 133.5% above this industry median. Based on the distribution chart, Accretion Nutraveda ranks #186 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #186 out of 961 companies for Operating Margin %. This places Accretion Nutraveda in the top 19% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.59. Accretion Nutraveda's value of 17.72% is 133.5% above this benchmark. Historically, Accretion Nutraveda's own Operating Margin % has ranged from 16.42 to 23.00 over the past decade. While the company's 10-year median is 20.82 vs. the industry median of 7.59, Accretion Nutraveda has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.59, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Nutraveda's current Operating Margin % of 17.72% is 133.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current Operating Margin % is 17.72%, which is 15% below median its own 10-year median of 20.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current Operating Margin % of 17.72%. The current Operating Margin % is 17.72%, which is 15% below median its 10-year median of 20.82 and 133.5% above the Drug Manufacturers industry median of 7.59. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current Operating Margin % is 17.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
